Form 4 for IMVT Immunovant, Inc.
Accepted 2024-04-04 00:00:00 ET · period of report 2024-04-02 · accession 0001764013-24-000046 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-04-04 | 2024-04-02 | IMVT | Barnett Eva Renee | CFO | A - Grant | $0.00 | +55.0K | 375.4K | +17% | $0 |
| D | 2024-04-04 | 2024-04-02 | IMVT | Barnett Eva Renee | CFO | A - Grant | $0.00 | +68.7K | 68.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-04-02 | A | A | 54,978 | $0.00 | 375,398 | D | — | — | (F1) These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on April 2, 2025, and the remainder will vest in substantially equal installments on a quarterly basis over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. |
| 2 | Derivative | Stock Option (right to buy) | 2024-04-02 | A | A | 68,723 | $0.00 | 68,723 | D | $30.78 · — to 2034-04-02 | 68,723 Common Stock | (F2) The shares underlying the options will vest as to 25% of the shares on April 2, 2025 and the remainder will vest in 36 substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. |